HEC68498 / HEC Pharm - LARVOL DELTA

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PIK3CA • PTEN

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd. | Recruiting ➔ Active, not recruiting | N=72 ➔ 12 | Trial completion date: Oct 2021 ➔ Dec 2022 | Trial primary completion date: Feb 2021 ➔ Jun 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PIK3CA • PTEN

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects (clinicaltrials.gov) - P1; N=55; Completed; Sponsor: Sunshine Lake Pharma Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Sunshine Lake Pharma Co., Ltd.

Clinical • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PIK3CA • PTEN

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects (clinicaltrials.gov) - P1; N=55; Active, not recruiting; Sponsor: Sunshine Lake Pharma Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2019 ➔ Mar 2022

Clinical • Enrollment closed • Trial completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases